BioCryst Pharmaceuticals Q4 Earnings Call Highlights

BioCryst highlighted the FDA’s approval in December 2025 of ORLADEYO oral pellets for children ages 2 to less than 12 . Chief Development Officer Dr. Bill Sheridan said the company is continuing marketing authorization applications in other major regions. Management described the unmet need as significant, noting that HAE and related attacks are underdiagnosed in younger children and that prophylaxis usage is about half that of adults.Gayer emphasized patient persistence and a “super responder” population f ...